206449-93-6

Basic information

• Product Name: rac Lafutidine
• Synonyms: rac Lafutidine
• CAS NO: 206449-93-6
• Molecular Formula: C22H29N3O4S
• Molecular Weight: 431.55
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 206449-93-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 94-99°C
• Boiling Point: 704.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.252
• Storage Temp.: Amber Vial, -20?C Freezer
• Solubility: Chloroform (Slightly), Dichloromethane (Slightly), DMSO (Slightly), Methanol (Sl
• PKA: 13.13±0.46(Predicted)
• Stability: Light Sensitive
• CAS DataBase Reference: rac Lafutidine(CAS DataBase Reference)
• NIST Chemistry Reference: rac Lafutidine(206449-93-6)
• EPA Substance Registry System: rac Lafutidine(206449-93-6)

Safety Data

• Hazardous Substances Data: 206449-93-6(Hazardous Substances Data)

Usage

Chemical Properties

rac Lafutidine is Off-White Solid

Uses

Different sources of media describe the Uses of 206449-93-6 differently. You can refer to the following data:
1. rac Lafutidine is a second generation histamine H2-receptor antagonist. Lafutidine is used as an antiulcerative.
2. Second generation histamine H2-receptor antagonist. Antiulcerative.

Upstream product

• 118289-18-2 2-Bromo-4-[1,3]dioxolan-2-yl-pyridine 
• 110-89-4 piperidine 
• 123855-55-0 p-nitrophenyl 2-(furfurylsulfinyl)acetate 
• 118289-21-7 2-[(Z)-4-(4-[1,3]Dioxolan-2-yl-pyridin-2-yloxy)-but-2-enyl]-isoindole-1,3-dione 
• 118289-19-3 2-[4-(2-tetrahydropyranyloxy)-(Z)-2-buten-1-yloxy]-4-(1,3-dioxolan-2-yl)-pyridine 
• 118287-95-9 N-[(Z)-4-(4-Formyl-pyridin-2-yloxy)-but-2-enyl]-2-(furan-2-ylmethanesulfinyl)-acetamide 
• 146270-01-1 2-chloro-4-(1-piperidinomethyl)-pyridine 
• 146270-02-2 (Z)-4-(Piperidin-1-ylmethyl)-2-((4-((tetrahydro-2H-pyran2-yl)oxy)but-2-en-1-yl)oxy)pyridine 
• 118289-23-9 N-[(Z)-4-(4-[1,3]Dioxolan-2-yl-pyridin-2-yloxy)-but-2-enyl]-2-(furan-2-ylmethanesulfinyl)-acetamide 
• 118289-20-6 4-[4-(1,3-dioxolan-2-yl)-2-pyridyloxy]-(Z)-2-buten-1-ol 
• 118289-22-8 (Z)-4-(4-[1,3]Dioxolan-2-yl-pyridin-2-yloxy)-but-2-enylamine 

Relevant articles and documents

Method for manufacturing lafutidine crystal with high purity

The present invention relates to a method for manufacturing a lafutidine crystal form with high purity. The method for manufacturing a novel lafutidine crystal form of the present invention produces a desired crystal form according to temperature control after dissolution, thereby being able to be easily applied to production (scale-up) and stably manufacture the lafutidine crystal form with high purity.

Increasing the Purity of Lafutidine Using a suicide Substrate

When preparing lafutidine, we found that the main impurity was dihydrolafutidine. On the basis of the chemical structure of dihydrolafutidine and the mechanism of its production, we decided to use a suicide substrate in the drug preparation to increase the purity of lafutidine. By calculating the energy barrier of the reduction reaction with a quantum-chemical method and evaluating the appropriate physicochemical properties of the terminal olefins, we chose 1-hexene as the suicide substrate to effectively control the formation of dihydrolafutidine in the synthesis of lafutidine. The experimental results showed that the content of the impurity, dihydrolafutidine, decreased from 1.5% to less than 0.05%, proving that using a suicide substrate is an effective method to reduce the formation of the relevant byproduct in drug production. In addition, this method is operationally simple and is suitable for industrial applications.

Lafutidine hydroxylamine hydrochloride method of preparation

The invention relates to a novel chemical synthetic method for lafutidine, and in particular relates to a method for preparing the lafutidine from hydroxylamine hydrochloride serving as aminolysis reagent. The method comprises the following steps of: (1) reacting a compound in a formula 4 with the hydroxylamine hydrochloride and sodium hydroxide so as to obtain a compound in a formula 2; (2) carrying out condensation on the compound in the formula 2 and a compound in a formula 3 so as to obtain the lafutidine in a formula 1. The whole preparation process is as shown in the specification. When in preparation of the key intermediate the compound in the formula 2, the hydroxylamine hydrochloride is chosen for substituting other reagents for aminolysis reaction, and the prepared lafutidine product has higher purity and can reach 99.88%; compared with the condition that the aminolysis reagent is removed from the intermediate, the hydroxylamine is easier to remove; and furthermore, the hydroxylamine hydrochloride is a solid reagent, has high purity and high stability, and industrial production is more easily realized.